$41,500,000 Settlement in Zetia and Vytorin Ineffectiveness Cases
Zetia and Vytorin class action suits were filed in several different states on behalf of patients and medical insurers who paid for the drug which apparently had no positive medical benefits. The lawsuits alleged that the drug makers pursued profits, without concern for whether the drug would have an impact on the health of users. The Zetia and Vytorin class action suits sought reimbursement for the cost of the prescription or for the difference between the cost of the prescription and what the generic would have cost. Barry Eichen, Esq. of Eichen Crutchlow Zaslow, LLP sat on the Vytorin Steering Committee which assisted in the settlement of these cases for $41.5 million.
See NY Times Article: Schering and Merck Are Settling Vytorin Suits